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Switching From
Prasugrel to Clopidogrel
Navigating in Unknown Waters*
Dominick J. Angiolillo, MD, PHD, Fabiana Rollini, MD
Jacksonville, Florida
Dual antiplatelet therapy with aspirin and a P2Y12 receptor
antagonist is the cornerstone of treatment to prevent recur-
rent atherothrombotic events in patients with acute coro-
nary syndrome (ACS) and undergoing percutaneous coro-
nary interventions (PCI) (1). Clopidogrel is the most widely
used platelet P2Y12 receptor inhibitor. Despite the clinical
efficacy of clopidogrel, numerous studies have shown a
broad inter-individual variability in the response to this
antiplatelet agent (2). Importantly, patients with high
See page 158
(HPR) and low (LPR) platelet reactivity while receiving
clopidogrel therapy have an increased risk of recurrent
ischemic events, including stent thrombosis and bleeding
complications, respectively (3,4). These findings have set
the basis for investigations aimed to define a “therapeutic
window” of platelet reactivity that defines a range of P2Y12
receptor-mediated antiplatelet effects associated with a re-
duced risk of ischemic and bleeding complications (Fig. 1)
(5). The broadening of the armamentarium of P2Y12
receptor inhibitors currently available for clinical use, in-
cluding prasugrel and ticagrelor, have indeed represented an
important step forward toward reaching such therapeutic
goals (6). These novel generation P2Y12 receptor inhibitors
are characterized by potent antiplatelet effects and a greater
reduction in atherothrombotic recurrences compared with
clopidogrel in ACS patients (6). However, despite these
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switch a patient from a more potent P2Y12 receptor inhib-
itor to clopidogrel. These include the higher risk of bleed-
ing, development of side effects, and increased costs of these
new agents compared with generic clopidogrel. However, to
date studies have mostly focused on the effects of switching
from clopidogrel to a novel generation P2Y12 receptor
nhibitor, and despite being broadly performed in clinical
ractice, there is a paucity of information on switching from
ne of the novel generation P2Y12 receptor inhibitors to
lopidogrel (7).
In this issue of JACC: Cardiovascular Interventions, Ker-
eis et al. (8) describe the results of an observational study
valuating the pharmacodynamic (PD) effects of switching
rom prasugrel to clopidogrel. In this study, a total of 300
igh-risk ACS patients treated with prasugrel (10 mg/day)
ere studied. Platelet reactivity was assessed with multiple
D assays after 15 days of treatment. The VerifyNow P2Y12
assay (Accumetrics, San Diego, California) was used to
define the optimal therapeutic window of platelet reactivity,
defined as 30 to 208 P2Y12 reaction units (PRU). Patients
elow and above these thresholds were identified as having
PR and HPR, respectively. The primary objective of the
tudy was the variation in LPR and HPR rates before and
fter the switch. Patients with LPR or those deemed to be
t high risk of bleeding were considered for a switch to
lopidogrel (75 mg/day) therapy, at the discretion of the
reating physician. Platelet reactivity was evaluated again 15
ays after switching from prasugrel to clopidogrel. A total of
1 (10.3%) prasugrel-treated patients, mostly (93.5%) pre-
Figure 1. Impact of Platelet Reactivity on the Balance Between Safety
and Efficacy
A “therapeutic window” of on-treatment platelet reactivity might delineate
the risk for ischemic and bleeding complications. This can potentially vary
according to the patient phenotype, such as clinical presentation (acute
coronary syndrome [ACS] vs. stable patient), glucose control (diabetes mel-
litus [DM] vs. non-DM patient), renal function (chronic kidney disease [CKD]
vs. normal renal function), and age (elderly vs. non-elderly). Adapted, with
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167senting with LPR, were switched to clopidogrel. Switch
from prasugrel to clopidogrel was associated with a signif-
icant 10-fold increase in platelet reactivity and a marked
reduction (10%) in LPR rates. However, this was associ-
ted with an increase in HPR from null while receiving
rasugrel to 29% after switching to clopidogrel. Overall,
his led to a greater percentage of patients within the
ptimal therapeutic window following the switch accord-
ng to VerifyNow PRU thresholds. The exploratory
linical observations showed that minor bleeding de-
reased after switch from 32.2% to 9.7%; there were no
ajor bleeding events or ischemic recurrences in this
tudy population.
The major strength of this investigation by Kerneis et al.
s that it is the first study in a clinical setting to assess the
D effects of switching from prasugrel to clopidogrel.
lthough the study was not designed to assess the clinical
mpact of this antiplatelet switching approach, the authors
rovide PD data that in larger investigations have shown to
e surrogates of worse outcomes (3,4). Therefore, although
o ascertainments on the safety and efficacy can be made,
he data reported can provide some guidance on what to
xpect from a PD standpoint when switching from prasu-
rel to clopidogrel in a population with characteristics
imilar to that studied in the present investigation (mostly
epresented by patients with LPR while receiving prasug-
el). There are, however, some considerations that need to
e made that highlight the largely unknown impact of
witching from prasugrel to clopidogrel in clinical practice.
First, the study reports the results of an observational
egistry in which the decision to switch from prasugrel to
lopidogrel was at the discretion of the physician who was
ware of the PD results. Therefore, this analysis suffers from
ignificant study entry bias. This is further reinforced
ecause most patients (93.5%) being switched had LPR, but
ot all patients with LPR were switched.
Second, the observation that after switching to clopdigrel
ore patients were within the therapeutic window with the
erifyNow P2Y12 assay needs to be interpreted with caution.
In fact, as mentioned in the preceding text, most patients being
switched in this study had LPR while receiving prasugrel, and
thus these findings might be a reflection that these patients
metabolize thienopyridines more efficiently, increasing their
likelihood of also being good responders to clopidogrel.
Whether this can be attributed to any specific clinical charac-
teristic or genetic make-up of these patients cannot be extrap-
olated from this study. Of note, although the switching
strategy allowed a higher percentage of patients to be within
the therapeutic window with the VerifyNow assay, these
percentages were actually worse with the other PD assays used
in this investigation.
Third, the study does not provide insights on how
switching from prasugrel to clopidogrel affects platelet
reactivity in patients within the optimal therapeutic windowof platelet reactivity while taking prasugrel. This is indeed of
crucial importance, because these comprised most of the
patients in this study. Prasugrel has been shown to have a
more favorable metabolism than clopidogrel, which trans-
lates into more consistent PD effects (6). Therefore, this
might raise suspicion that switching patients to clopidogrel
when they are within the optimal therapeutic window while
taking prasugrel might account for an increase in platelet
reactivity and thus potentially expose them to a higher risk
of atherothrombotic events.
Fourth, the therapeutic window defining optimal levels of
platelet reactivity was somewhat arbitrary. In fact, although
the threshold of HPR seems to have been validated in
several studies, there remains large uncertainty on the best
threshold of LPR. In fact not all studies have been success-
ful in identifying a threshold of platelet reactivity associated
with increased bleeding and it has also varied in those who
have (3). Differences in bleeding definitions, clinical setting,
and patient population among other factors can contribute
to these findings (Fig. 1) (5). It might also be argued that
the therapeutic window might also vary over time in ACS
patients, as indirectly reflected by the increase in bleeding
complications and reduction in ischemic benefit over time
with prasugrel (9). Thus, a switch only after 15 days of
prasugrel treatment in LPR patients might be premature,
because the highest risk period for ischemic recurrences—
including stent thrombosis—is during the first months after
an acute event, and thus lower levels of platelet reactivity
might be desirable during this time frame.
Ultimately, no conclusions with regard to safety and
efficacy should be made on the basis of the clinical findings
from this study, which was limited to only 15 days of
observation in a highly selected population. Of note, most
studies to date have failed to demonstrate that modification
of P2Y12 receptor inhibiting antiplatelet treatment regimen
n the basis of the results of platelet function testing can
mpact safety and efficacy, underscoring that routine testing
s still not ready for prime-time (5).
Defining how and when to optimally switch antiplatelet
herapy remains an unmet clinical need. Further studies are
equired to better define PD profiles of switching strategies
f patients with more wide-ranging levels of platelet reac-
ivity while receiving a given P2Y12 receptor inhibitor. Most
mportantly, an improved understanding of how switch-
ng from newer-generation P2Y12 receptor inhibitors,
which provide more effective anti-ischemic protection
but increased bleeding potential compared with clopi-
dogrel, impacts patient outcomes. Only larger-scale reg-
istry and randomized clinical trial data will better delin-
eate the safety and efficacy of such switching antiplatelet
strategy and thus guide clinicians navigating in these
unknown waters.
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